Endocrine Abstracts

Hypoparathyroidism, a rare endocrine disorder of insufficient parathyroid hormone, leads to hypocalcemia and often hyperphosphatemia. The PARADOX study assessed the clinical and personal disease impact from the affected patients’ perspective.Patients ≥18 years and diagnosed ≥6 months ago completed a non-validated, self-reported, web-based survey.Three hundred and seventy-four US adults (mean age, 49 years; women, 8...

In hypoparathyroidism, inadequate levels of parathyroid hormone (PTH) result in hypocalcemia and often hyperphosphatemia. Large doses of calcium (Ca) and active vitamin D are typically used to manage symptoms, although these are often associated with complications and do not address the underlying PTH deficiency. In the phase III REPLACE trial, 24 weeks of treatment with rhPTH(1–84) was associated with maintained serum Ca without urine Ca excretion increases despite clini...

Chronic hypoparathyroidism affects ~2.5/10 000 individuals in the European Union and is classified as a rare disorder. There is limited knowledge of the natural history and epidemiology of this disease. Publications frequently represent a single center’s experience and information across the population of patients with hypoparathyroidism is lacking and needed. To fill the gap, a voluntary global hypoparathyroidism patient registry (PARADIGHM) was initiated by NPS Pharmace...

PTH promotes conversion of 25-hydroxyvitamin D (25[OH]D) to 1,25-dihydroxyvitamin D (1,25[OH]2D), thus stimulating intestinal calcium and phosphate absorption. Because of low PTH levels in hypoparathyroidism, patients are prescribed calcitriol. Patients are predisposed to hyperphosphatemia owing to loss of PTH-stimulated phosphate excretion by the kidneys. Effects of rhPTH(1–84) on vitamin D metabolism and serum phosphate were studied.In ...

Hypoparathyroidism, a rare disorder characterized by absent or low levels of parathyroid hormone (PTH), often results from thyroid surgery. However, nonsurgical etiologies are present in >10% of patients. Data about this group of patients are limited.In this post hoc REPLACE (NCT00732615, EudraCT2008-005063-34) analysis, baseline characteristics and response to 50–100 μg/day rhPTH(1-84) in patients with postsurgical or nonsurgical ...

Hypoparathyroidism is a rare endocrine deficiency due to inadequate amounts of parathyroid hormone (PTH) and is characterised by hypocalcaemia and hyperphosphataemia. Current management regimens with large amounts of oral calcium and active vitamin D do not adequately control mineral homeostasis and can lead to complications in many patients. The phase III REPLACE and RELAY clinical trials established the efficacy and safety of once-daily s.c. injection of r...